Molecular Profiles of Upper-Airway Remodeling

Abstract

Upper-airway remodeling is a dynamic, multifactorial process implicated in a variety of chronic respiratory diseases, including asthma, chronic rhinosinusitis, and obstructive sleep apnea. This review dissects the molecular profiles associated with upper-airway remodeling, highlighting key mediators, regulatory pathways, and cellular events. Emphasis is placed on recent advances in molecular diagnostics and targeted therapies, offering clinically relevant insights for healthcare professionals aiming to optimize management of upper-airway diseases.

Introduction

Upper-airway remodeling refers to structural and functional changes in the airway wall, resulting from persistent inflammation and injury. These alterations impact airway caliber, compliance, and function, contributing to disease chronicity and therapeutic resistance. Understanding the molecular underpinnings of upper-airway remodeling provides a foundation for precision medicine approaches in otolaryngology and pulmonology. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, diagnostic modalities, management strategies, and emerging therapies with reference to the molecular landscape of remodeling.

Epidemiology / Disease Burden

Remodeling of the upper airway is prevalent in multiple chronic diseases, affecting millions globally. In asthma, up to 40% of patients exhibit airway remodeling, correlating with disease severity and poor control. Chronic rhinosinusitis with nasal polyposis (CRSwNP) shows remodeling in the majority of surgical specimens, while obstructive sleep apnea (OSA) is increasingly linked to airway structural changes. The burden extends to healthcare utilization, quality of life, and increased morbidity due to refractory symptoms and complications.

Pathophysiology

At the molecular level, upper-airway remodeling is orchestrated by a complex interplay of cytokines, growth factors, and matrix-modifying enzymes. Key mediators include transforming growth factor-beta (TGF-β), interleukin-13 (IL-13), matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs). Persistent inflammation, typically eosinophil or neutrophil-driven, triggers epithelial-mesenchymal transition (EMT), goblet cell metaplasia, and subepithelial fibrosis. Vascular remodeling, smooth muscle hyperplasia, and extracellular matrix (ECM) deposition further compromise airway function. Recent transcriptomic analyses reveal distinct molecular signatures in allergic versus non-allergic remodeling, underscoring the need for endotype-driven therapies.

Risk Factors

Risk factors for upper-airway remodeling include genetic predisposition, chronic allergen exposure, recurrent infections, tobacco smoke, and environmental pollutants. Polymorphisms in genes encoding TGF-β, ADAM33, and IL-4 receptor alpha have been associated with increased susceptibility. Early-onset and poorly controlled airway inflammation, especially in childhood, predispose to irreversible structural changes. Comorbidities such as gastroesophageal reflux and obesity modulate the remodeling process through systemic inflammatory pathways.

Clinical Features

Clinically, upper-airway remodeling manifests as persistent airflow limitation, mucosal thickening, polyp formation, and tissue rigidity. Patients may present with chronic nasal obstruction, rhinorrhea, hyposmia, and refractory asthma symptoms. In OSA, pharyngeal wall thickening and soft tissue hypertrophy contribute to nocturnal airway collapse. Importantly, remodeling is often insidious, and its presence correlates with disease severity, poor response to corticosteroids, and increased risk of surgical intervention.

Diagnosis

Diagnosis of upper-airway remodeling relies on a combination of clinical evaluation, imaging, and molecular assessment. High-resolution computed tomography (HRCT) and magnetic resonance imaging (MRI) visualize mucosal thickening, polypoid changes, and bony remodeling. Endoscopic examination allows direct assessment and biopsy. Molecular profiling using immunohistochemistry, PCR, and next-generation sequencing can identify key mediators, endotypes, and potential therapeutic targets. Peripheral and tissue eosinophilia, elevated periostin, and MMP-9 levels are emerging as non-invasive biomarkers of active remodeling.

Treatment & Management

Management strategies aim to control inflammation, prevent progression, and restore airway function. Intranasal and systemic corticosteroids remain the mainstay for inflammatory suppression. Biologics targeting IL-5, IL-4/13, and IgE are effective in selected endotypes, especially in eosinophilic CRSwNP and severe asthma. Anti-fibrotic agents, although largely experimental, are under investigation for their potential to reverse established remodeling. Surgical interventions, including endoscopic sinus surgery and nasal polypectomy, address anatomical obstruction but may not halt molecular progression without concurrent medical therapy.

Recent Advances / Emerging Therapies

Recent advances in molecular profiling have enabled precision medicine approaches, stratifying patients by endotype and likelihood of response to targeted therapies. Dupilumab, an IL-4Rα antagonist, has demonstrated efficacy in reducing polyp size and improving symptoms in CRSwNP. Mepolizumab and benralizumab, targeting the IL-5 axis, are beneficial in eosinophilic asthma and nasal polyposis. Novel agents targeting TGF-β signaling and MMP activity are in early-phase trials. Omics technologies, including transcriptomics and proteomics, hold promise for the discovery of novel biomarkers and drug targets, enabling earlier intervention and individualized treatment.

Guideline Recommendations

Current guidelines from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the Global Initiative for Asthma (GINA) emphasize early recognition of remodeling features, use of endotype-directed biologic therapies, and judicious application of surgical intervention. Regular monitoring using nasal endoscopy, imaging, and biomarker assessment is recommended for high-risk patients. Multidisciplinary management involving allergists, pulmonologists, and otolaryngologists optimizes outcomes, particularly in refractory cases.

Conclusion

Upper-airway remodeling is a pivotal determinant of disease persistence and treatment resistance in chronic airway disorders. Advances in molecular profiling have transformed our understanding of its pathogenesis, enabling the development of targeted therapies and personalized care pathways. Continued research into the molecular drivers and clinical implications of remodeling will further refine management strategies, ultimately improving patient outcomes and quality of life.